Comparison of biodistribution profile of monoclonal antibodies nanoparticles and aptamers in rats with breast cancer.

Comparison of biodistribution profile of monoclonal antibodies nanoparticles and aptamers in rats with breast cancer.

Artif Cells Nanomed Biotechnol. 2017 May;45(3):598-601

Authors: Cerqueira-Coutinho C, Missailidis S, Alessandra-Perini J, Machado DE, Perini JA, Santos-Oliveira R

Abstract
The use of monoclonal antibodies and aptamers is growing every single day, as the use of nanoparticle systems. Although most of the products are under investigation, there are a few commercialized products available at the market, for human consume. In this study, we have compared three formulations (aptamer anti-MUC1, monoclonal antibody - Trastuzumab and monoclonal antibodies nanoparticles - PLA/PVA/MMT trastuzumab) to identify their profile as also to understand their behavior into an alive biological system. In this direction the radiolabeling of the products were done and they were all tested in animals (in vivo) in two conditions: healthy rats and breast cancer induced animals. The results showed that the nanoparticle has the better biodistribution profile, followed by the aptamer. We conclude that more studies and a global effort to elucidate the biological behavior of drugs and especially nano-drugs are necessary.

PMID: 28211299 [PubMed - in process]

http://ift.tt/2kz851Y